BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/12/2022 4:01:56 AM | Browse: 295 | Download: 725
 |
Received |
|
2021-07-09 13:37 |
|
Peer-Review Started |
|
2021-07-09 13:42 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-11-11 03:05 |
|
Revised |
|
2021-11-19 08:54 |
|
Second Decision |
|
2021-12-06 03:22 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-12-08 05:07 |
|
Articles in Press |
|
2021-12-08 05:07 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-01-03 11:14 |
|
Publish the Manuscript Online |
|
2022-01-12 04:01 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Neurosciences |
| Manuscript Type |
Retrospective Study |
| Article Title |
N6-methyladenine-modified DNA was decreased in Alzheimer’s disease patients
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Shuang Lv, Xiao Zhou, Yi-Ming Li, Tao Yang, Shu-Juan Zhang, Yu Wang, Shu-Hong Jia and Dan-Tao Peng |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Key R&D Program of China |
2016YFC1306300 |
| National Natural Science Foundation of China |
81974220 |
|
| Corresponding Author |
Dan-Tao Peng, PhD, Chief Physician, Professor, Department of Neurology, China-Japan Friendship Hospital, No.2 Yinghuayuandong Street, Beijing 100029, China. pengdantao2000@163.com |
| Key Words |
Alzheimer disease; N6-methyladenine; DNA; Montreal Cognitive Assessment; Apolipoprotein E; Cognitive dysfunction |
| Core Tip |
Although Alzheimer’s disease (AD) cannot be cured, early diagnosis and treatment can greatly improve the prognosis of AD patients. Thus, we aimed to identify biomarkers of AD that can be useful in the clinic. The diagnostic criteria for AD were strictly employed in the study. We found that N6-methyladenine (m6A) DNA adenine methylation may be a novel biomarker of AD. Twenty subjects underwent 18F-AV-45 (florbetapir) positron emission tomography to test this assertion. In addition, the global m6A DNA methylation level was also correlated with cognition level. |
| Publish Date |
2022-01-12 04:01 |
| Citation |
Lv S, Zhou X, Li YM, Yang T, Zhang SJ, Wang Y, Jia SH, Peng DT. N6-methyladenine-modified DNA was decreased in Alzheimer’s disease patients. World J Clin Cases 2022; 10(2): 448-457 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i2/448.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i2.448 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
